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Mitochondrial ferritin (FtMt) is an iron storage protein belonging to the ferritin family but, unlike the 
cytosolic ferritin, it has an iron-unrelated restricted tissue expression. FtMt appears to be preferentially 
expressed in cell types characterized by high metabolic activity and oxygen consumption, suggesting 
a role in protecting mitochondria from iron-dependent oxidative damage. The human gene (FTMT) is 
intronless and its promoter region has not been described yet. To analyze the regulatory mechanisms 
controlling FTMT expression, we characterized the 5′ flanking region upstream the transcriptional 
starting site of FTMT by in silico enquiry of sequences conservation, DNA deletion analysis, and ChIP 
assay. The data revealed a minimal promoter region and identified the presence of SP1, CREB and YY1 
as positive regulators, and GATA2, FoxA1 and C/EBPβ as inhibitors of the transcriptional regulation. 
Furthermore, the FTMT transcription is increased by acetylating and de-methylating agent treatments 
in K562 and HeLa cells. These treatments up-regulate FtMt expression even in fibroblasts derived from 
a Friedreich ataxia patient, where it might exert a beneficial effect against mitochondrial oxidative 
damage. The expression of FTMT appears regulated by a complex mechanism involving epigenetic 
events and interplay between transcription factors.
Mitochondria are the sites in which iron is transformed into heme and Fe-S clusters (ISC) by specific biosynthetic 
pathways1,2. For this reason these organelles are the major users of cellular iron and, similarly to the cell, relies 
on iron transport, storage, and regulatory proteins to maintain iron homeostasis3. One of them, mitochondrial 
ferritin (FtMt) belongs to the family of ferritins, the iron storage proteins, and exerts its role specifically in mito-
chondria, where it is efficiently imported and localized inside the matrix4.
Structure and function of FtMt are similar to the cytosolic ferritin with some peculiarity5. Its 3D structure 
results analogous to that of human H-ferritin (FtH). Besides, its biochemical properties are remarkably similar to 
those of FtH, except for its ferroxidase activity6. In fact, iron binding, oxygen consumption and proton produc-
tion kinetic experiments comparing FtMt and FtH revealed striking differences between the two proteins in iron 
oxidation and hydrolysis chemistry, despite their similar ferroxidase centers7. However, FtMt acts as an efficient 
ferritin by readily incorporating and oxidizing iron in vitro7.
Previous functional studies on cellular models indicated that FtMt bound mitochondrial iron and its expres-
sion had a profound effect on cellular iron homeostasis, since it induced iron delocalization from cytosol to 
mitochondria8–12. The in vivo data on Ftmt−/− mouse models revealed only minor defects: i) the sideroblast/
siderocyte formation in mice fed vitamin B6 (pyridoxine) deprivation diet13 and ii) the higher sensitivity of heart 
mitochondria to the toxicity of doxorubicin14.
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Mitochondrial ferritin is encoded by a nuclear gene (FTMT) on chromosome 5q23.1. Genes homologous to 
FTMT have been identified in plants15,16, in insect, as Drosophila melanogaster17 and in mammals, like chimpan-
zee, mouse, rat and dog18. FTMT is an intronless gene, lacking the typical TATA or CCAAT box upstream the 
ATG start codon and codifies for a precursor peptide with a mitochondrial targeting signal4,18. This DNA region 
belongs to a group of non-X-linked bona fide promoter CpG island that is densely methylated in normal somatic 
tissues19. In particular, the 220 base pairs long segment upstream the ATG codon is characterized by a highly 
methylated GC-rich content19.
Despite of the relative large amount of data on FtMt functional role, little evidences have been collected on 
the regulation of its expression as well as on the mechanisms of its cell/tissue specific expression. In contrast with 
the cytosolic ferritin, FTMT mRNA does not contain any functional IRE sequence18, meaning that its expression 
is not iron dependent. In mammalians, it shows a tight tissue-specific expression pattern18. In mouse, FTMT 
expression is restricted to a limited number of cell types with a pattern apparently linked to the oxidative met-
abolic activity of the cells, suggesting that it might protect the mitochondria from iron-dependent oxidative 
damage rather than be associated to iron storage function20. In Sideroblastic Anemia patients, FTMT is highly 
expressed in ring sideroblasts where it detoxifies mitochondrial iron overload caused by defective heme synthe-
sis21. Enhanced FTMT expression is demonstrated in brains of Alzheimer’s Disease (AD)22 and in Restless Legs 
Syndrome (RLS) affected patients23. In the case of AD, it was proposed that overexpression of FTMT, induced by 
oxidative stress, decreased the amount of toxic Aβ PP peptide24, while in RLS its enhancement could be detrimen-
tal and contribute to the pathologic cytosolic iron deprivation23. Furthermore, the increased expression of FTMT 
was detected in cardiomyocytes of Friedreich Ataxia (FRDA) patients25. A more recent study showed a down-
regulation of FTMT in Neuroblastoma and in Neurospongioma, where it has been proposed that FTMT could 
be used as a target to inhibit neuronal cell proliferation through its overexpression26. However, FTMT expression 
may also be detrimental, as showed in K562 erythroid cells where its overexpression reduced JAK/STAT signaling 
and increased apoptosis27,28.
In this work, we investigate the transcriptional regulation of FTMT and we identify the putative promoter 
region, comprising the minimal promoter as well as a positive and a negative transcriptional factors target regions. 
We also explored the possibility of epigenetic control as responsible for FTMT silencing in a tissue-specific man-
ner. Furthermore, given the protective role of FtMt described in FRDA10,11, we analyzed a hypothetic epigenetic 
intervention to increase FTMT expression in FRDA fibroblasts.
Results
Identification of putative promoter region of FTMT . To identify the putative promoter region of 
FTMT gene we looked for conserved consensus sequences upstream the transcription-starting site among differ-
ent species by in silico analysis. In particular, the region from − 2040 base pairs to + 600, corresponding to UCSC 
chr5:121185610:121189119 on Human GRCh37 Assembly (hg19), showed a sequence identity of 70% to mouse 
and 93% to macaque (Fig. 1A). We cloned the sequence − 1884 bp to − 1 from the transcription-starting site in 
front of a luciferase reporter construct and we made a series of 5′ and 3′ deletions to test their effect on luciferase 
expression in order to determine the region responsible for basal promoter activity. These vectors were trans-
fected into HeLa cells and we analyzed their promoter activity compared to the cells transfected with the empty 
vector (mock) (Fig. 1B,C). In the 5′ deletions experiments the − 1884 construct had an activity of 10 fold respect 
to mock, which we used as value reference (Fig. 1B). The segment − 902/− 1 and fragment − 491/− 1 showed a 
similar promoter activity to − 1884/− 1 fragment; on the contrary the − 217/− 1 and − 91/− 1 resulted in a dimin-
ished promoter activity (Fig. 1B). Analysis of 3′ truncated constructs presented complementary results. In fact, 
the − 1884/− 1128 fragment showed a strong decreased activity, while − 1884/− 874 had an increased activity. 
Finally − 1884/− 464 and − 1884/− 217 showed a weakened promoter activity (Fig. 1C). To better characterize the 
results obtained, we made smaller 3′ truncation, between − 1128 and − 464. The − 1884/− 777 and − 1884/− 631 
segments showed 50 fold increased activity respect to mock, indicating the presence of a putative activator region. 
The − 1884/− 521 and − 1884/− 464 segments showed a strong reduction of activity indicating the presence of a 
putative inhibitory region (Fig. 1C). In conclusion we identified the presence of two regions: one from − 1128 
to − 631, which contains activating regulatory elements, and one from − 631 to − 521 that contains suppressing 
regulatory elements. We also found that the 491bp fragment upstream transcription starting site contains a min-
imal promoter, confirmed by the absence of activity with the deletion of this region from the entire construct 
(− 1128/− 521 and − 1128/− 464) (Fig. 1D).
Analysis of transcription factors for FTMT promoter. To identify transcription factors involved in 
positive and negative regulation for FTMT gene, we made an in silico analysis of the sequence using ClustalW2, 
MatInspector and PROMO databases. We predicted transcription factors to bind to the region identified by 
the luciferase assay, between − 1128 and − 521 bp and we selected the transcription factors conserved also in 
mouse and macaque (Fig. 2A). Among them, in the region containing activating regulatory elements, we selected 
CREB and YY1, that bind to the positive strand, and SP1 that binds to the negative strand (Matrix similarity in 
MatInspector: CREB = 0.92, SP1 = 0.97, YY1 = 0.84 and dissimilarity margin in PROMO: CREB = not found, 
SP1 = not found, YY1 = 0.49%). In the region encompassing suppressing regulatory elements, we selected 
FoxA1 and C/EBPβ , which bind to the positive strand, and GATA2 that binds to negative strand (Matrix simi-
larity in MatInspector: FoxA1 = 0.96, C/EBPβ = 0.92, GATA2 = not found and dissimilarity margin in PROMO: 
FoxA1 = 3.23%, C/EBPβ = 2.24%, GATA2 = 6.67%).
To confirm the results obtained by in silico analyses, we studied in vitro whether the transcription factors 
interact with the two regulatory regions of the FTMT promoter by performing chromatin immunoprecipitation 
(ChIP) analysis. Chromatin solutions isolated from K562 were incubated with specific antibodies for the selected 
transcription factors (see Materials and Methods). DNA isolated by ChIP from the K562 samples was analyzed by 
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quantitative real time PCR (Fig. 2B), using the oligonucleotides specific for the two identified regulatory regions 
(activator and inhibitor, Table 2). The results showed that the regions identified in the FTMT promoter were occu-
pied by the transcription factors. Indeed, the region in the FTMT promoter containing the activating regulatory 
elements was immunoprecipitated by the transcription factors CREB, SP1, and YY1 with significant difference 
compared to the non-specific IgG used as negative control (Fig. 2B left panel). Similarly, the region containing the 
suppressing regulatory elements was immunoprecipitated by the transcription factors FoxA1, Gata2 and C/EBPβ 
(Fig. 2B, right panel). Non-precipitated chromatin input was used as PCR positive control (Fig. 2B). In order 
to verify the putative interaction between the different transcription factors, we performed chromatin immu-
noprecipitation for two of them, one binding the activating regulatory region (CREB) and one the suppressing 
regulatory elements (FoxA1) (Fig. 2C, left panel). Then, we amplified the immunoprecipitated chromatin with oli-
gonucleotides specific for the single activating and suppressing regulatory elements (schematized in Fig. 2C, right 
panel) and with a pair of oligonucleotides specific for a more wide region containing both elements (schematized 
in Fig. 2C, right panel). The amplification with the oligonucleotides including both regulatory regions resulted 
undetermined, suggesting that the two regulatory regions are physically separated. On the contrary, the amplifi-
cation of the suppressing regulatory elements, after immunoprecipitation with the transcriptional factor binding 
the activating regulatory region (and viceversa), resulted measurable, with significant difference compared to the 
Figure 1. Promoter identification by in silico analysis and luciferase assay. (A) Mammalian conservation 
of FTMT 5′ genomic sequence, corresponding to chr5:121185610:121189119 on Human GRCh37 Assembly 
(hg19). The conservation summary is adapted from ECR Browser47. (B) Luciferase assay on promoter sequence 
with 5′ and (C) 3′ deletions to identify the promoter activity. Left panels show the scheme of the constructs. 
Right panels show the quantification of luciferase emission with the indicated constructs normalized to empty 
vector. The plots represent the mean + /− SD of three independent experiments. (D) Scheme showing the 
position of positive (green) and negative (pink) regulatory and minimal promoter (blue) regions, resulting from 
luciferase assay.
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Figure 2. Identification of transcription factors and Chromatin Immuno Precipitation (ChIP) analysis.  
(A) Conservation of identified activator and repressor sequence in human, macaque, and mouse. In red the 
region containing positive regulatory elements, from − 874 to − 777, in blue the region comprising negative 
regulatory elements, from − 631 to − 521. The location of putative binding sites for transcription factors are 
boxed: positive transcription factors are in green while negative are in pink. Solid line represent transcription 
factors bind to positive strand DNA, while dotted line indicate the ones bind to negative strand DNA. The 
sequence alignment was created with ClustalW2; transcription factors were identified by MatInspector and 
PROMO Alggen. (B) Chromatin immunoprecipitation (ChIP) prepared from K562 cells with the indicated set 
of antibodies specific for transcription factors selected by in silico analysis of the FTMT promoter. The amount 
of co-precipitated DNA is evaluated by qRT-PCR using oligonucleotides specific for positive and negative 
regulatory elements. On the left panel, ChIP of activator region: CREB, SP1 and YY1 transcription factors 
interacting with positive regulatory elements. On the right panel, ChIP of repressor region: FOXA1, GATA2 and 
C/EBPβ transcription factors interacting with negative regulatory elements. IgG represents the negative control 
with non-specific antibodies. Input represents the positive control of chromatin without immunoprecipitation. 
The plots represent the mean + /− SD of four independent experiments in triplicate, analyzed with One-way 
Anova with Bonferroni post test, **p < 0.01. (C) Chromatin immunoprecipitation (ChIP) as in B, the chromatin 
immunoprecipitated with the indicated transcription factors interacting with positive or negative regulatory 
elements was amplified also with the oligonucleotides specific for the opposite and the total regulatory elements 
(act = activator, inh = inhibitor, tot = total regulatory elements). N.D. = not detectable. X = possible broken 
region. The plots represent the mean + /− SD of two independent experiments in triplicate, analyzed with One-
way Anova with Bonferroni post test, *p < 0.05, ***p < 0.001.
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non-specific IgG (Fig. 2C, left panel). This result implies that the transcription factors bound to activating and 
suppressing regulatory region interact to form transcriptional machinery complex.
Epigenetic control of FTMT expression. In silico analysis on UCSC Genome Browser reveals the 
presence of large CpG islands in the FTMT promoter that includes several CpG hotspot both in the promoter 
region and in the gene sequence (Fig. 3A evidenced in blue). On the basis of these evidences (Fig. 3A) and by 
genome-wide profiling of DNA methylation data19, we expected that HeLa cells should be fully methylated while 
K562 cells should be partially methylated. To experimentally confirm the in silico data, we performed methylated 
specific PCR and, as expected, the CpG regions in the FTMT promoter in HeLa cells resulted fully methylated 
while the CpG island in K562 was only partially methylated (Fig. 3B). Treatment of these two cell lines with 5 μ M 
of 5-Aza-2′ -deoxycytidine (Aza, an inhibitor of DNA methylation) for 72 h resulted in a decreased amount of 
methylated DNA both in HeLa and in K562 cell line. Consistently, mRNA of HeLa cells was not detectable in 
basal condition, and it appeared after Aza treatment while in K562 a detectable level of mRNA expression was 
found, which was up-regulated by treatment with Aza (Fig. 3C). Moreover, the supplement of 1 mM Sodium 
Butyrate (NaB, an histone deacetylase (HDAC) inhibitor) for 72 h had an additive effect in K562 but not in HeLa 
cells; in fact the combination effect of Aza and NaB in K562 cells induced a 5,8 fold increase compared to basal 
FTMT expression (Fig. 3C). For this reason we decided to use K562 cell line treated with NaB and Aza for further 
analysis.
To further verify if FTMT expression is under control of epigenetic events, we transfected the 1884 bp segment 
of the putative promoter region in front of a luciferase reporter sequence in K562 (Fig. 3D). Luciferase assay 
showed a significant increase of its expression after treatment with Aza or with NaB respect to the basal condi-
tion, further enhanced by the treatment with both substances (Fig. 3D). To better define the promoter activity 
we assayed the effect of the 3′ truncations constructs. Constructs with deletion of densely methylated region at 3′ 
(− 464 and − 521) did not respond to treatment with Aza and NaB. Vice versa, the simultaneous treatment with 
Aza and NaB in − 631 bp and in − 777 bp fragments induced more than 150 fold increase of luciferase activity 
(Fig. 3E).
FTMT expression in FRDA fibroblasts. To evaluate the epigenetic control of FTMT in pathological con-
dition, we checked the epigenetic landscape in a cell line obtained from a FRDA patient compared with that of 
K562 cells through methylation specific PCR (Fig. 4A). FTMT resulted to be fully methylated at basal level in 
control and FRDA patient, but we can appreciate a significant decrease of the amount of methylated DNA after 
Aza treatment (Fig. 4A). Surprisingly, we were not able to detect a correspondent increase of demethylated DNA, 
Plasmid Forward Oligonucleotide (5′ to 3′) Reverse Oligonucleotide (5′ to 3′)
FTMT RT1: TATGCGTCCTACGTGTACT RT2: TGTTCCGGCTTCTTGATGT
GAPDH GAPDHf: TCCCATCACCATCTTCCAG GAPDHr: ATGAGTCCTTCCACGATACC
INSL6 INSL6f: AAAAACTCTGCGGCCATGC INSL6r: CCCAACTGTTTACTGCTTCTTCC
FTMT activator FTMTf: GAGTGCAGTGGCTCGATCT FTMTr: GTGGCAGGCTGCTGTAGT
FTMT inhibitor FWI2: CTAACCTTGTGATCCGCC RVI5: ATGAGATACTGTAGGCCGG
FTMT total regulatory FTMTf: GAGTGCAGTGGCTCGATCT RVI5: ATGAGATACTGTAGGCCGG
Methylated sequences TCGATTTTACGTTAAGAGGGTC GATCTACCTAAAATCCAAAAAACG
Un-methylated sequences TGATTTTATGTTAAGAGGGTTGG AATCTACCTAAAATCCAAAAAACACC
Table 2. Primers for quantitative real time PCR.
Plasmid Forward Oligonucleotide (5′ to 3′) Reverse Oligonucleotide (5′ to 3′)
pGL2Mt (1893 bp: − 1884 + 9) MITA: ACGTAGCCTCGAGATGTGGTTGACAGAAGGCAGGTGCAAACA MITC: CGATACAAGCTTAGCGCCGCCTCCTTGGAAGT
pGL2MtA (226 bp: − 217 + 9) MIT1: ACGTAGCCTCGAGTGCGCTGGCCTCCGCCTAGA MITC
pGL2MtC (100 bp: − 91 + 9) MIT2: ACGTAGCCTCGAGTGCCTAGGGCCACGTTCTGATCAG MITC
pGL2MtF (911 bp: − 902 + 9) MIT5: ACGTAGCCTCGAGACGGAGTCTTGCTCTGTCGCCCA MITC
pGL2MtG (500 bp: − 491 + 9) MIT6: ACGTAGCCTCGAGATGTACACTTGCTTTGGATGTGGACCT MITC
pGL2MtH (1667 bp: − 1884 − 217) MITA MITH1: CTATACAAGCTTGATGCCCAGTCACGATTCCGT
pGL2MtM (1010 bp: − 1884 − 874) MITA MTM: CTATACAAGCTTCAGCCTGGGCGACAGAGCAAGA
pGL2MtM1 (1107 bp: − 1884 − 777) MITA MTM1: CTATACAAGCTTTGGTGGCAGGCTGCTGTAGT
pGL2MtM2 (1253 bp: − 1884 − 631) MITA MTM2: CTATACAAGCTTATACTGTAGGCCGGGTGCCGT
pGL2MtM3 (1363 bp: − 1884 − 521) MITA MTM3: CTATACAAGCTTTGGAAACAATTGCCAGCATAGTGGGA
pGL2MtN (1420 bp: − 1884 − 464) MITA MITN: CTATACAAGCTTAGGTCCACATCCAAAGCAAGTGTACATA
pGL2MtO (756 bp: − 1884 − 1128) MITA MITO: CTATACAAGCTTAAGGGTAAGCACGCAGAAGAAAGTTCA
Table 1.  Primers for plasmids construction.
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Figure 3. Epigenetic control of FTMT expression. (A) Schematic representation of the putative methylated 
regions in the FTMT promoter predicted by UCSC Genome Browser. Regions that can be methylated are shown 
in blue, numbers indicate position on the sequence respective to ATG, starting and stop codons (ATG and Stop, 
respectively) are indicated. (B) Methylation specific PCR showing methylated (M) and unmethylated (U) DNA 
in HeLa and K562 cells, untreated (− ) or treated (+ ) with 5 μ M Aza for 72 h. Arrow indicates PCR product size. 
(C) Expression of FTMT by qRT-PCR in HeLa and K562 cells untreated, treated with the demethylating agent 
(5 μ M Aza), with the histone deacetylase inhibitor (1 mM sodium butyrate, NaB) or both for 72 h. The plots 
represent the mean + /− SD of three independent experiments in triplicate, analyzed with One-way Anova with 
Bonferroni post test, *p < 0.05, ***p < 0.001. (D) Luciferase assay of the putative promoter region to evaluate 
epigenetic contribution to FTMT expression in K562 cells. Luciferase activity of the full promoter region in 
basal condition (Untreated) or after treatment as in panel C. The plots represent the mean  
+/− SD of three independent experiments in triplicate, analyzed with One-way Anova with Bonferroni post 
test, *p < 0.05, **p < 0.01, ***p < 0.001. (E) Luciferase activity of promoter region with 3′ deletions upon 
treatment described in panel C. The plots represent the mean + /− SD of three independent experiments in 
triplicate, analyzed with Two-way Anova with Bonferroni post test, ***p < 0.001.
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may be due to the low sensitivity of the experimental approach (Fig. 4A). Nevertheless, the FTMT mRNA incre-
ment become evident at quantitative level in an healthy subject (control) and FRDA fibroblasts after treatment 
with 5 μ M Aza and 1 mM NaB for 72 h (Fig. 4B). In fact, the analysis of FTMT expression by qRT-PCR showed 
that untreated control and FRDA cells had no detectable FTMT transcript, while demethylation and acetylation 
increased the expression of FTMT, even if at lower level than in K562 in basal condition (Fig. 4B). The control 
of efficacy of demethylation treatment was checked through the increment of INSL6 expression, a gene that is 
epigenetically regulated (Fig. 4C)19,29. Thus, the comparison between the FTMT expression in control and FRDA 
fibroblasts and K562 cells indicated that the treatment to modify the epigenetic control is less efficient in FRDA 
fibroblasts respect to the erythroid cells (Figs 3B and 4A,B).
Figure 4. FTMT expression in Friedreich ataxia fibroblasts and K562 cells. (A) Methylation specific PCR 
showing methylated (M) and unmethylated (U) DNA in untreated (− ) K562 cells and in primary fibroblasts 
from a FRDA patient untreated (− ) or treated (+ ) with 5 μ M Aza for 72 h. Arrow indicates product size.  
(B) mRNA level of FTMT in control and FRDA fibroblasts and K562 cells treated for 72 h with 5 μ M Aza 
and 1 mM NaB analyzed by qRT-PCR. (C) The expression of INSL6 gene is analyzed to confirm effective 
demethylation. The plots represent the mean + /− SD of three independent experiments in triplicate, analyzed 
with Mann-Whitney test *p < 0.05, ***p < 0.001.
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Discussion
The data previously collected on the physiological role of FtMt5 and its peculiar distribution pattern20 suggested 
that its expression might be regulated at transcriptional level in a specific tissue- and cell- type manner. An exam-
ple of this uneven tissue distribution is its high expression in mouse testis, where the protein is mainly localized 
in spermatozoa and it is easily detectable by specific immunoassay, while the same assay is unable to reveal its 
presence in almost all of the other tissues20. In order to elucidate FTMT expression regulation we focused our 
attention on the 2000 bp upstream the ATG codon, where we identify the FTMT promoter region. By cloning 
the FTMT upstream genomic region with higher conservation between human and mouse, we determined the 
sequence responsible for basal promoter activity. It is contained in the 491 bp fragment upstream the transcrip-
tional start site, as confirmed by the absence of luciferase activity in case of deletion of this region from the 
experimental construct. We also found two other pivotal regions: one that contains activating regulatory elements 
and the other one that contains inhibitory regulatory elements. Deleting the region corresponding to activator, 
in fact, we had no luciferase activity, meaning that proteins bind this DNA sequence to promote the transcrip-
tion of FTMT. On the contrary, eliminating the region corresponding to inhibitor, we observed an increment of 
luciferase activity, suggesting that within this deleted region some factors prevent the transcription. To identify 
transcription factors binding these FTMT regulatory regions, we performed an in silico analysis and selected 
some of them depending on the score of matches in DNA sequences, on their conservation in mouse FTMT 5′ 
region and on their functional features (Fig. 2A). On this basis, among the identified transcription factors we 
selected the six of which we experimentally confirmed the binding. From the analysis of DNA region containing 
the activating regulatory elements, we selected: YY1 (Yin Yang 1), CREB (c-AMP-response-element-binding 
protein), and SP1 (Specificity Protein 1). YY1 is a multifunctional transcription factor, ubiquitously expressed30, 
that could cause a looser conformation of chromatin allowing the access to other transcription factors31. In addi-
tion, it is able to bind CREB, which is activated by phosphorylation in neurons in conditions of hypoxia and 
oxidative stress by CREB-kinases32,33. Usually, CREB assemble a transcriptional complex able to advance histone 
acetylation that alters the conformation of chromatin33. SP1 is essential for cell growth and differentiation34. In 
particular in neurons, SP1 DNA-binding complex is induced by oxidative stress, especially as early response to 
cell stress35. We can suppose that in consequence of oxidative stress, YY1 gives an early response binding DNA 
and inducing looser conformation of chromatin; this helps the connections of CREB and SP1. Then, they connect 
to transcription machinery resulting in FTMT expression. The control of the expression by CREB and SP1 may 
explain the peculiarity of FtMt pattern of expression detected in mouse that highlighted the presence of protein 
exclusively in cell type with high energy demand that are more susceptible to ROS formation20. From the analysis 
of DNA region containing the inhibitor elements, we selected: GATA binding protein 2 (GATA2), Forkhead-box 
protein A1 (FoxA1) and CCAAT-enhancer binding proteins beta (C/EBP β ). All of them play essential role in 
the development and differentiation36–39, thus they might act as inhibitors for FTMT during the differentiation 
process of tissues where its expression is not necessary. In particular, GATA2 is a key transcriptional regulator 
of haematopoiesis, highly expressed in pluripotent hematopoietic stem cells and in early erythroid cells40. In 
physiological condition FtMt is not detectable in erythroid cells, while it is demonstrated that in pathological 
condition, like myelodysplastic syndrome with ring sideroblasts (MDS-RARS), it is specifically highly expressed 
in the ring- syderoblasts4,21,28. Actually, it exists a close correlation between the presence of FtMt and the iron 
specific Prussian blue staining indicating that mitochondrial ferritin is the form of iron deposited in perinuclear 
mitochondria of ring sideroblasts28.
Interestingly, recent studies have demonstrated that subjects carrying GATA2-sequence variations have 
high risk to develop MDS40, suggesting that this pathogenetic event might be responsible for the up-regulation 
of FtMt in the disorder, where we have shown to interfere with JAK2/STAT5 pathways leading to ineffective 
erythropoiesis27,28.
The ChIP experiments evidenced the existence of a complex in which the different transcriptional factors 
closely interact, suggesting that they could be simultaneously involved in up/down regulation of the FTMT 
expression. Further experiments are needed to clarify in deeper detail this mechanism.
In addition to the control of FTMT expression by transcription factors, we also demonstrated the presence of 
an epigenetic control that might enhance the tissue-specific FTMT gene silencing. Indeed, previous data showed 
that the level of FtMt is critical for maintaining cellular iron homeostasis8,9,27. When protein is expressed at high 
level it acts as an iron sink in mitochondria causing cytosolic iron deprivation, for this reason its amount has to 
be strictly regulated to preserve cellular iron balance. However, it is also demonstrated that its role is important 
during oxidative damage10,11. Thus, its physiological amount must be a compromise between its detrimental and 
beneficial action, and FtMt requirement can be different, based on specificity of type of cells.
To investigate the possibility to modulate the FTMT epigenetic control in pathological models, we chose 
FRDA, a neurological disorder caused by the deficiency of frataxin (FXN), a mitochondrial iron-chaperon 
involved in iron sulfur cluster biosynthesis41. Here, the protective role of FtMt was demonstrated11, due to its 
beneficial effect on iron-dependent chronic oxidative stress that characterize the disease, and where the action of 
epigenetic therapy was already shown42. In fact, in FRDA model, HDAC inhibitor leads to an increased expression 
of frataxin mRNA42 via the inhibition of deacetylation43. In a previous work, the presence of FtMt was revealed in 
FRDA fibroblasts by immunoblotting assay, using an anti-heart ferritin polyclonal antibody with low specificity 
for FtMt44. Differently, we were not able to identify FtMt in our control and FRDA fibroblasts under basal condi-
tion, whereas, it was feasible to reveal FTMT expression in control and FRDA fibroblasts by the combined treat-
ment with the inhibitor of deacetylation and demethylating agents (Fig. 4). In these conditions, FXN mRNA was 
not increased in FRDA fibroblasts (not shown), suggesting that the HDAC inhibitor used was not adequate, both 
for type and concentration. In fact, it was demonstrated that it is necessary a combined inhibition of HDAC 1, 2 
and 3 to up-regulate FXN gene45. However, the condition to up-regulate FTMT is milder than the one necessary to 
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induce FXN, thus, we proposed to take in consideration an epigenetic therapy in FRDA patients to increase at least 
FTMT expression, since it could be useful to help protecting these patients from mitochondrial oxidative stress.
In conclusion, even if further study has to be done to identify the complete transcription machinery respon-
sible of FTMT expression and silencing, we identified the promoter region of FTMT and we demonstrated a 
double opposite control of its expression. We located specific regulatory sequences and recognized the respective 
positive and negative transcription factors. Furthermore, we confirmed that epigenetic factors play a role in the 
control of FTMT expression. We hypothesized that methylated cytosines in the FTMT GC islands are recognized 
by methyl binding protein MeCP2 that can recruit histone de-acetylases, which maintain condensed chromatin. 
The reagents Aza and NaB make the DNA accessible to transcription factors and activate FTMT expression. Our 
findings sustain that the moderate induction of FTMT expression by epigenetic therapy could be useful in disease 
characterized by oxidative stress, as FRDA.
Materials and Methods
Database research. In order to understand the methylation status of FTMT promoter region, we exploited 
the data available from the ENCODE project46. In particular, we checked for methylation status of CpG islands 
using the track “CpG Methylation by Methyl 450 K Bead Arrays from ENCODE/HAIB” and extracted the 
genomic sequence and positions of probes mapping up to 3 kb upstream of FTMT promoter.
The sequence comparisons were performed by ECR Browser47 and ClustalW248. The transcription binding 
sites were analyzed by MatInspector (Genomatix Software GmbH)49 and by PROMO (Alggen)50.
Plasmid construction. The pcDNA3-FtMt plasmid, encoding the entire FtMt protein precursor, has been 
described previously8. Plasmid containing the promoter region and fragments were amplified from human 
genomic DNA by PCR using primers (Table 1) containing XhoI and HindIII recognition sites. The promoter 
fragments (− 1884 bp/− 1 bp) were cloned into a promoterless luciferase reporter vector, pGL2. We designed oli-
gonucleotides to amplify fragments deleted at 5′ (− 902/+ 9, − 491/+ 9; − 217/+ 9, − 91/+ 9) or at 3′ (− 1884/− 217, 
− 1884/− 464,− 1884/− 521, − 1884/− 631, − 1884/− 777, − 1884/− 874, − 1884/− 1128) (Table 1).
Cell culture, transfection and luciferase assay. HeLa cells (ATCC, cat. n° CCL-2) and a fibroblast cell 
line (ATCC, cat. n° PCS-201-012) for control and derived from one FRDA patient (1037SS previously described 
in11) were grown in high glucose DMEM supplemented with 10% FBS, penicillin/streptomycin antibiotics and 
glutamine at 37° and 5% CO2. The human erythroleukemic K562, (ATCC, cat. n° CCL-243) cells were cultured 
in RPMI supplemented with 10% FBS, penicillin/streptomycin antibiotics and glutamine at 37° and 5% CO2. 
HeLa and K562 cells were transiently transfected using Lipofectamine 2000 (Invitrogen, San Giuliano Milanese, 
Italy). HeLa cells were chosen because they are an easier transfection cell system, while K562 cells because they 
have been previously described as a model of low FTMT expression in basal condition19. Epigenetic evaluation 
was done by treatment of cells for 72 h with 5 μ M of 5-Aza-2′ -deoxycytidine (decitabine or Aza, Sigma-Aldrich, 
Milan, Italy), a demethylating agent, and with 1 mM of Sodium Butyrate (NaB, Sigma-Aldrich, Milan, Italy), an 
histone deacetylase inhibitor (HDAC inhibitor).
Luciferase assay was performed following 48 h transfection. Renilla luciferase and firefly luciferase activities 
were analyzed using the Dual-Luciferase® Reporter Assay System (Promega, Milan, Italy) following the mani-
facturer’s instructions. The firefly luciferase activities were normalized using the Renilla luciferase activity and 
luciferase vector pGL2-basic values were used as negative controls.
Chromatin Immuno Precipitation (ChIP). Formaldehyde crosslinking and chromatin immunopre-
cipitation assay on K562 cells, equivalent to 3 × 107 for each ChIP was performed as previously described51. 
Chromatin samples were immunoprecipitated O/N at 4 °C rotating by incubation with the following antibodies: 
rabbit polyclonal to CREB (ab31387), rabbit polyclonal to SP1 (ab13370), rabbit polyclonal to YY1 (ab38422), 
rabbit polyclonal to FOXA1 (ab23738), rabbit polyclonal to GATA2 (ab22849), rabbit monoclonal to CEBP Beta 
(ab32358, Abcam, Cambridge, UK) and rabbit IgG (Cell Signaling Technology, Leiden, The Netherlands). Protein 
G-Dynabeads were washed in PBS, 0.5% BSA O/N at 4 °C. The day after, IP samples were added to Dynabeads 
and incubated for 2 h at 4 °C rotating. The beads were then washed 3 times for 10 min each at 4 °C rotating. After 
the last wash, the supernatant was removed, 120 μ l of decrosslink solution (100 mM NaHCO3, 1% SDS) was 
added in each sample and incubated O/N at 65 °C with shaking. The day after, the samples were incubated with 
Proteinase K (0.4 mg/ml) for 2 h at 55 °C with shaking and subsequently with RNAse (0.15 mg/ml) for 2 h at 37 °C 
with shaking. DNA samples were purified by GE Healthcare PCR purification kit, following the kit instructions 
(GE Healthcare, Milan, Italy). The DNA was eluted in 50 μ l of dd H2O and 1–2 μ l were used for real-time poly-
merase chain reaction (qRT-PCR). qRT-PCR was performed by SYBR green TaqMan® with primers designed to 
specifically amplify human FTMT promoter and more specifically activator and inhibitor regions (Table 2) using 
ABI7900HT fast real time PCR system (Applied Biosystems, Monza, Italy).
Methylation specific PCR. DNA methylation was analyzed using bisulfite-modified genomic DNA. 
Aliquots of 500 ng of isolated genomic DNA were bisulfite modified using the EZ Methylation Bisulfite Kit (Zymo 
Research, Pero, Italy) according to manufacturer’s instructions. The applied primer pairs (Table 2) gave PCR 
products size of 187 bp for methylation sequences and of 186 bp for un-methylated sequences. Primers were 
applied to a final concentration of 0.5 μ M. Cycling conditions were as follows: 10 min at 95 °C, followed by 34 
cycles of 30 s at 94 °C, 30 s at 55 °C (methylated sequences)/57 °C (un-methylated sequences), and 45 s at 72 °C, 
and a final 7 min extension step at 72 °C. After amplification, PCR products were subjected to 2% agarose gel elec-
trophoresis to control and establish the purity of amplicones. The PCR products were purified using QIAquick 
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Gel Extraction Kit (QIAGEN, Milan, Italy) according to the manufacturer’s instructions. Five ng of PCR products 
were then prepared for sequencing in order to verify amplicones specificity. Sequences were obtained using ABI 
PRISM® 3130XL automatic sequencer (Applied Biosystems).
RNA extraction and qRT-PCR. Total RNA was extracted from cells using the RNeasy Mini Kit (QIAGEN, 
Milan, Italy) as per the manufacturer’s directions. RNA quantity was assessed with Nanodrop (NanoDrop 
Technologies, Wilmington, DE) and equal amounts of total RNA (4 μ g) was incubated with 1 U DNaseI 
(Invitrogen, Monza, Italy); it was reverse transcribed using the Superscript III RT kit (Invitrogen, Monza, Italy). 
Samples without reverse transcriptase were included as negative controls. The resulting cDNA was preamplified 
by TaqMan PreAmp Master Mix Kit (Applied Biosystems) as per the manufacturer’s directions. qRT-PCR was 
performed by TaqMan® Gene Expression Assay using ABI7900HT fast real time PCR system. FTMT mRNA 
expression is relative to housekeeping gene HPRT1 (Hypoxanthine Phosphoribosyltransferase1). (FTMT: 
Hs00893202_s1; HPRT1: Hs02800695, both Applied Biosystems). To verify Aza treatment efficacy, primers were 
designed to specifically amplify human INSL6 and GAPDH as housekeeping (Table 2) and qRT-PCR was per-
formed by Sybr green TaqMan® with, using ABI7900HT fast real time PCR system.
Statistical analyses. The data, except where otherwise indicated, are reported as the mean + /− SD values 
or as representative of at least three independent experiments with similar results. Data were analyzed using 
GraphPad Prism. In general, for normally distributed data two tailed unpaired one- or two-way ANOVA followed 
by Bonferroni post test was used. For non-normally distributed data, Mann-Whitney rank sum test was used. 
*, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively. A p value < 0.05 was considered statistically 
significant.
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